A Phase 1/2, Multicenter, non-randomized, Open Label Study of ABSK061 to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy in Children with Achondroplasia (ACH)

At a glance
Trial Overview
Trial Details
Interventions
Trial History
References

Trial Profile

A Phase 1/2, Multicenter, non-randomized, Open Label Study of ABSK061 to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy in Children with Achondroplasia (ACH)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 061 (Primary)
Indications Achondroplasia
Focus Adverse reactions

Most Recent Events

15 Apr 2025 New trial record
26 Mar 2025 According to Abbisko Therapeutics media release, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the IND application for ABSK061, for the treatment of children with Achondroplasia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com